Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 23 February, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Suven Life Sciences Ltd

About the Company - Suven Life Sciences Ltd

Suven Life Sciences Ltd. is a Public Limited Listed company incorporated on 09/03/1989 and has its registered office in the State of Andhra Pradesh, India. Company’s Corporate Identification Number(CIN) is L24110TG1989PLC009713 and registration number is 009713. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 11.84 Cr. and Equity Capital is Rs. 14.54 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
Pharmaceuticals8-2-334, SDE Serene Chambers, Hyderabad Telangana 500034info@suven.com
http://www.suven.com
Management
NamePosition Held
Mr. Venkateswarlu JastiChairman & CEO
Mrs. Sudharani JastiWhole Time Director
Mrs. J A S PadmajaDirector
Prof. Seyed E HasnainDirector
Mr. M GopalakrishnaDirector
Mr. Santanu MukherjeeDirector

Suven Life Sciences Ltd. Share Price Update

Share PriceValue
Today₹107.00
Previous Day₹104.75

Basic Stock Data of Suven Life Sciences Ltd

Market Cap 2,294 Cr.
Current Price 105
High / Low129/45.0
Stock P/E
Book Value 15.5
Dividend Yield0.00 %
ROCE52.7 %
ROE53.5 %
Face Value 1.00

Data Source: screener.in

Competitors of Suven Life Sciences Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Lincoln Pharmaceuticals Ltd 1,292 Cr. 645715/31914.8 2730.24 %21.7 %15.5 % 10.0
IOL Chemicals & Pharmaceuticals Ltd 2,446 Cr. 417536/27214.2 2711.18 %13.7 %9.68 % 10.0
Biocon Ltd 32,608 Cr. 272307/19227.2 1580.54 %5.92 %4.78 % 5.00
Zota Health Care Ltd 1,384 Cr. 535535/270 39.50.19 %2.32 %7.42 % 10.0
Solara Active Pharma Sciences Ltd 1,714 Cr. 476494/286 4070.00 %1.80 %1.44 % 10.0
Industry Average7.4 Cr46911.24229.70.43%9.09%7.76%9

Suven Life Sciences Ltd Quarterly Results

MonthSep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Sales9222144443343
Expenses27282345293724252655343227
Operating Profit-18-27-22-43-28-32-20-21-22-52-32-28-24
OPM %-196%-1,764%-1,383%-2,118%-2,340%-733%-467%-596%-494%-1,719%-1,208%-737%-768%
Other Income22150006026613
Interest0000000000000
Depreciation1111111222222
Profit before tax-17-26-22-39-28-34-21-16-23-51-28-24-13
Tax %6%7%-0%0%0%0%0%0%0%0%0%0%0%
Net Profit-16-24-22-39-28-34-21-16-23-51-28-24-13
EPS in Rs-0.82-1.28-1.13-2.05-1.48-1.76-0.95-0.75-1.06-2.34-1.27-1.10-0.58

Suven Life Sciences Ltd Quarterly Chart

Suven Life Sciences Ltd Profit & Loss

MonthMar 2006Mar 2007Mar 2008Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales881121175214995436252861313121412
Expenses779610536139841442730012893134139147
Operating Profit111613159102129198-14-116-80-122-126-135
OPM %13%15%11%31%20%24%32%-5%-917%-593%-1,032%-928%-1,080%
Other Income11391921232714851426
Interest2355665211110
Depreciation344121821211144477
Profit before tax6116152981231960-106-77-122-118-116
Tax %2%-5%-32%28%26%29%37%15,038%11%7%0%0%
Net Profit61181097287124-24-94-72-122-118-116
EPS in Rs0.650.485.703.764.576.48-1.25-4.94-3.78-5.59-5.42-5.29
Dividend Payout %39%26%35%7%35%15%15%-80%0%0%0%0%

Suven Life Sciences Ltd Profit & Loss Yearly Chart

Suven Life Sciences Ltd Growth

Compounded Sales Growth
10 Years:%
5 Years:-54%
3 Years:2%
TTM:-21%
Compounded Profit Growth
10 Years:%
5 Years:%
3 Years:-13%
TTM:3%
Stock Price CAGR
10 Years:37%
5 Years:48%
3 Years:10%
1 Year:87%
Return on Equity
10 Years:%
5 Years:-39%
3 Years:-76%
Last Year:-53%

Suven Life Sciences Ltd Balance Sheet

MonthMar 2006Mar 2007Mar 2008Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital561213131313131313152222
Reserves8596955475836547552261315882354317
Borrowings244155109837134365321
Other Liabilities293038105747811862335391211
Total Liabilities143173199773751816919303182128108389350
Fixed Assets8396110172305306308222521383734
CWIP35410771025005400
Investments4520030127922300454664
Other Assets5368834944391993085815710322305252
Total Assets143173199773751816919303182128108389350

Suven Life Sciences Ltd Reserves and Borrowings Chart

Suven Life Sciences Ltd Cash Flow

MonthMar 2006Mar 2007Mar 2008Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 51641436810970-53-135-96-128-103
Cash from Investing Activity -9-20-16-110-39-311-13014656-22-261
Cash from Financing Activity 3136179-68-30-525335146396
Net Cash Flow-18-7212-39-23217-1814-5-432

Suven Life Sciences Ltd Financial Efficiency Indicators

MonthMar 2006Mar 2007Mar 2008Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days625311128393136366484022
Inventory Days2691972001651832223290
Days Payable11373157897891134
Cash Conversion Cycle218177154105144162231366484022
Working Capital Days125107139697363100237341,139285293
ROCE %11%8%13%15%24%-4%-54%-68%-143%-53%

Suven Life Sciences Ltd Financial Efficiency Indicators Chart

Suven Life Sciences Ltd Share Holding Pattern

MonthMar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Promoters60.00%60.00%60.00%60.00%64.98%64.98%64.98%69.56%69.56%69.56%69.56%69.56%
FIIs0.48%0.41%0.44%0.52%0.45%0.45%0.48%0.46%0.51%0.48%0.50%0.54%
DIIs0.66%0.44%0.44%0.44%0.46%0.39%0.12%0.11%0.11%0.08%0.01%0.01%
Public38.86%39.15%39.12%39.04%34.11%34.18%34.41%29.85%29.80%29.88%29.92%29.88%
No. of Shareholders77,65086,00881,47580,19581,03981,03880,11680,83878,63476,29180,95374,003

Suven Life Sciences Ltd Shareholding Pattern Chart

No. of Suven Life Sciences Ltd Shareholders

Suven Life Sciences Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)
Motilal Oswal S&P BSE Healthcare ETF6940.060.01

Suven Life Sciences Ltd ROCE Trend

Suven Life Sciences Ltd EPS Trend

Suven Life Sciences Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
FaceValue1.001.001.001.001.00
Basic EPS (Rs.)-6.63-9.57-5.67-7.40-1.88
Diluted EPS (Rs.)-6.63-9.57-5.67-7.40-1.88
Cash EPS (Rs.)-5.12-8.09-5.33-7.07-1.03
Book Value[Excl.RevalReserv]/Share (Rs.)17.216.618.4911.2618.79
Book Value[Incl.RevalReserv]/Share (Rs.)17.216.618.4911.2618.79
Revenue From Operations / Share (Rs.)0.620.811.061.1322.44
PBDIT / Share (Rs.)-5.39-8.05-5.68-7.991.01
PBIT / Share (Rs.)-5.69-8.35-6.02-8.320.16
PBT / Share (Rs.)-5.42-8.39-6.09-8.360.01
Net Profit / Share (Rs.)-5.42-8.39-5.67-7.40-1.88
NP After MI And SOA / Share (Rs.)-5.42-8.39-5.67-7.40-1.88
PBDIT Margin (%)-867.37-988.42-536.50-705.394.50
PBIT Margin (%)-915.70-1025.51-568.75-734.310.72
PBT Margin (%)-873.52-1029.98-574.80-738.140.05
Net Profit Margin (%)-873.52-1029.98-535.31-653.62-8.36
NP After MI And SOA Margin (%)-873.52-1029.98-535.31-653.62-8.36
Return on Networth / Equity (%)-31.51-126.88-66.80-65.72-9.99
Return on Capital Employeed (%)-32.81-121.80-68.13-68.100.78
Return On Assets (%)-30.41-112.92-56.18-51.78-7.87
Long Term Debt / Equity (X)0.000.000.000.010.01
Total Debt / Equity (X)0.000.010.000.010.01
Asset Turnover Ratio (%)0.020.030.040.040.42
Current Ratio (X)22.618.016.452.497.07
Quick Ratio (X)22.618.016.452.497.07
Inventory Turnover Ratio (X)0.000.000.000.001.14
Interest Coverage Ratio (X)-406.21-220.85-88.68-184.406.72
Interest Coverage Ratio (Post Tax) (X)-428.84-229.14-87.49-169.87-11.49
Enterprise Value (Cr.)872.721343.38849.81258.383321.88
EV / Net Operating Revenue (X)64.46113.4263.0517.9211.63
EV / EBITDA (X)-7.43-11.47-11.75-2.54258.33
MarketCap / Net Operating Revenue (X)78.07113.8566.4818.9011.62
Price / BV (X)2.8214.028.301.9013.89
Price / Net Operating Revenue (X)78.08113.8566.4818.9011.62
EarningsYield-0.11-0.09-0.08-0.34-0.01

Suven Life Sciences Ltd Profitability Ratios (%)

Suven Life Sciences Ltd Liquidity Ratios

Suven Life Sciences Ltd Liquidity Ratios (%)

Suven Life Sciences Ltd Interest Coverage Ratios (X)

Suven Life Sciences Ltd Valuation Ratios

Fair Value / Intrinsic Value of Suven Life Sciences Ltd

Fair Value: ₹126.88

The stock is undervalued by 20.83% compared to the current price ₹105

*Investments are subject to market risks

Strength and Weakness of Suven Life Sciences Ltd

StrengthWeakness
  1. The company has higher reserves (306.38 cr) compared to borrowings (33.62 cr), indicating strong financial stability.
  2. The company has shown consistent growth in sales (219.62 cr) and profit (4.08 cr) over the years.
  1. The stock is trading at a high valuation with an average P/B ratio of -5.64 and average Dividend Yield of -648.71%.
  2. The stock has a low average ROCE of -20.92%, which may not be favorable.
  3. The stock has a high average Working Capital Days of 167.67, which may not be favorable.
  4. The stock has a high average Cash Conversion Cycle of 114.17, which may not be favorable.

Should I Buy Suven Life Sciences Ltd Share Now?

  • Considering various financial indicators, investors might exercise caution regarding investment in Suven Life Sciences Ltd:
    1. Net Profit Margin: -873.52%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: -32.81% (Industry Average ROCE: 22.82%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. Interest Coverage Ratio (Post Tax): -428.84
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    4. Quick Ratio: 22.61
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    5. ✓ Stock P/E of N/A (Industry average Stock P/E: 36.56)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    6. ✓ Total Debt / Equity: 0.00
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis suggests exercising caution. It's advisable to conduct further research or consult with financial experts before considering any investment.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Suven Life Sciences Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE